Already a member? Sign in
Esomeprazole is a proton pump inhibitor. It is used for treatment of gastrointestinal reflux disease; for duodenal and gastric ulcers; and for conditions associated with hypersecretion of gastric acid, including Zollinger-Ellison syndrome.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Acid reflux | 295 | 65 |
|
|
|
|
|
| GERD (Gastroesophageal reflux disease) | 222 | 25 |
|
|
|
|
|
| Other | 74 | 6 |
|
|
|
||
| General health | 18 | 1 |
|
||||
| Increase effect of another treatment | 17 | 4 |
|
|
|
||
| Gastritis | 14 | 1 |
|
See all 645 patients currently taking Esomeprazole
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Esomeprazole
| Headaches | 2 | |
|---|---|---|
| Nausea | 1 | |
| Weight gain | 1 | |
| Indigestion | 1 | |
| Gas | 1 | |
| Breakthrough pain | 1 | |
| See all 9 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Esomeprazole. See all 18 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Expense | 30 | ||
| Did not seem to work | 26 | ||
| Doctor's advice | 21 | ||
| Course of treatment ended | 20 | ||
| Change in health plan coverage | 18 | ||
| Other | 18 | ||
| Side effects too severe | 9 | ||
| Personal research | 6 | ||
| Not indicated | 2 |
Adherence
Taking treatment as prescribed
Adherence of Esomeprazole
Always |
91 | 77% |
|
|---|---|---|---|
Usually |
22 | 19% |
|
Sometimes |
4 | 3% |
|
Never |
1 | 1% |
|
Burden
Difficulty being on treatment
Burden of Esomeprazole
Very |
0 | 0% |
|
|---|---|---|---|
Somewhat |
11 | 9% |
|
A little |
12 | 10% |
|
Not at all |
95 | 81% |
|
Cost
Paid out of pocket
Cost of Esomeprazole
$200+ |
3 | 3% |
|
|---|---|---|---|
$100-199 |
4 | 5% |
|
$50-99 |
12 | 14% |
|
$25-49 |
20 | 23% |
|
< $25 |
47 | 55% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on May 28, 2012.